MedPath
HSA Approval

TAFINLAR DISPERSIBLE TABLET 10MG

SIN17019P

TAFINLAR DISPERSIBLE TABLET 10MG

TAFINLAR DISPERSIBLE TABLET 10MG

June 3, 2024

NOVARTIS (SINGAPORE) PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantNOVARTIS (SINGAPORE) PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

TABLET, FOR SUSPENSION

ORAL

Medical Information

L01EC02

Manufacturer Information

NOVARTIS (SINGAPORE) PTE LTD

Novartis Pharma Stein AG

Active Ingredients

Dabrafenib mesylate eqv Dabrafenib

10mg

Dabrafenib

Documents

Package Inserts

Tafinlar PI.pdf

Approved: June 3, 2024

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

TAFINLAR DISPERSIBLE TABLET 10MG - HSA Approval | MedPath